Mr. Will is an operating executive with extensive experience founding, funding, operating, and selling medical device companies. Prior to EBR Systems, he led the negotiation of Ardian’s acquisition by Medtronic for over $800 million. Will was also founding Managing Director at Split Rock Partners and a Partner at St. Paul Venture Capital. Previously, he was Founder, Chairman & CEO of The Foundry, co-founding 11 companies there including Ardian, Evalve (acquired by Abbott Laboratories for $450 million), and Concentric Medical (acquired by Stryker for $135 million). Earlier in his career, Will served as CEO of AneuRx, acquired by Medtronic, growing to over $150 million the year of launch. Prior to that, he was President & CEO of Devices for Vascular Intervention, growing the business to 550 employees, $100 million revenue run rate, and acquisition by Eli Lilly. Will holds more than 30 issued patents and earned his Master of Science in Management from MIT and Bachelor of Science in Zoology from the University of Maryland.

Ms. Drexler is a serial entrepreneur with expertise in the fields of digital health, medical devices, and diagnostics. She currently serves on the boards of two other public companies, ResMed, Inc. and Outset Medical Inc., focusing on the compensation, nominating, and governance committees. Drexler also serves on the boards of two private companies: VIDA Diagnostics Inc., an artificial intelligence-powered lung imaging solutions company, and Tivic Health Systems, Inc., a bioelectric medicine company focused on relief of congestion and sinus pain. She also acts as a senior strategic advisor for other early-stage companies and spent 11 years on the board of the Keller Center for Innovation in Engineering Education at Princeton University. Drexler is an active mentor and advisor to Astia, a global nonprofit that supports high-potential female founders, as well as a mentor with StartX, the Stanford University incubator. She graduated magna cum laude with a Bachelor of Science in Chemical Engineering from Princeton University and earned an MBA with Honors from the Stanford University Graduate School of Business.

Dr. Evans is an experienced leader and CEO with a broad technical background across multiple industry sectors, including medical technology, manufacturing, power generation and distribution, and technical regulation and standards. Most recently she was the CEO of Engineers Australia, she also serves as the Chair of Building 4.0 CRC and as Director at GME Pty Ltd. Prior to her role with Engineers Australia, Evans was the CEO of Standards Australia. She has previously held positions in innovation initiatives, including Chair of MTPConnect (the Industry Growth Center for Medical Technologies and Pharmaceuticals) and was a member of the Industry 4.0 Advanced Manufacturing Forum Leadership group. Evans has been recognized as one of Australia’s 100 most influential engineers and as one of 100 Women of Influence. She holds a Bachelor of Engineering (Honors I) and a Ph.D. in Electrical Engineering from the University of Wollongong. Additionally, she holds an Honorary Doctorate from Swinburne University and is an Honorary Fellow of the University of Wollongong and Engineers Australia and a Fellow of the Australian Academy of Technological Sciences and Engineering.

Mr. Moody has served as a Director of EBR since 2017. He served as Medical Device Partner at M.H. Carnegie & Co. (from October 2013 to April 2022), where he made investments in medical device companies. He has also served since January 2010 as President of TM Strategic Advisors LLC, a management consultancy. Moody was previously a General Partner at Frazier Healthcare Ventures, a large U.S. based private equity and venture capital firm. Currently a Director of Cardiac Dimensions Pty Ltd., Renew Medical Pty Ltd., The Brain Protection Company Pty Ltd., and CurvaFix, Inc., Moody also serves on the board of Angel Flight West, a not-for-profit that provides free air transport for patients requiring long-distance travel for medical treatment. He holds a B.Eng. from the University of Southern Queensland and an M.S. in Management from the Massachusetts Institute of Technology (Sloan School).

‍

Dr. Nave has served as a Director of EBR since 2017. He is a Founder and Managing Director of Brandon Capital Partners and the CEO of the Medical Research Commercialization Fund. Nave previously served as the Director of Commercialization at the Baker Heart Research Institute. Currently a Director of The Australian Investment Council, Azura Ophthalmics, Inc., Certa Therapeutics Pty Ltd., Global Kinetics Corporation Ltd., OccuRx Pty Ltd., Osprey Medical Inc., PolyActiva Pty Ltd., and Que Oncology, Inc. Nave was Chairperson of Fibrotech Therapeutics Pty Ltd. at the time of its successful sale to Shire Plc and a Director of Spinifex Pharmaceuticals, Inc. at the time of its sale to Novartis International AG. He holds a B.Sc. (Honors) and a Ph.D. in Endocrinology and Physiology from the University of Melbourne and is a member of the Australian Investment Council.

Dr. Steinhaus retired in 2019 as Vice President and General Manager of the Heart Failure Business for the Cardiac Rhythm and Heart Failure Division at Medtronic plc. He joined Medtronic in 2005, after 20 years of cardiology (electrophysiology) practice. Steinhaus’ responsibilities at Medtronic included bringing the physician voice to CRHF, identifying future opportunities in new product development, and serving as a liaison to government agencies, professional societies, and medical groups. Closely associated with research and academia, performing extensive clinical studies in implantable cardiac devices and leads, he served as Chair of the Department of Cardiology and Director of the Electrophysiology Department at the Mid America Heart Institute and St. Luke’s Hospital and Director of the Electrophysiology Fellowship Program at the University of Missouri at Kansas City School of Medicine. Since leaving Medtronic, he has served as a consultant and board member to multiple medical device companies. Currently the Executive Chairman of the board of Enopace Biomedical Ltd., a company that produces therapeutic neuromodulation devices for the treatment of heart failure, he graduated magna cum laude from Harvard College and received his medical doctorate from Harvard Medical School as part of the Harvard M.I.T. program in Health Sciences and Technology, with AOA honors.

Mr. McCutcheon has over 40 years of sales, marketing, and general management experience in medical devices. McCutcheon started his career at American Hospital Supply (acquired by Baxter International) and has spent the past 20 years at start-ups, including DVI (acquired by Eli Lily), Perclose (acquired by Abbott Laboratories), Emphasys Medical (acquired by Pulmonx), Ventus Medical, and Ceterix Orthopaedics (acquired by Smith & Nephew). He has served on numerous Boards including Emphasys Medical, Ventus Medical, Disc Dynamics, Zeltiq (ZLTQ), Advanced Stent Technologies (acquired by Boston Scientific), and LuMend (acquired by Johnson & Johnson). McCutcheon holds Bachelor of Arts degrees in Economics and Psychology from the University of California, Los Angeles, and a Master of Business Administration from the UCLA Anderson Graduate School of Management.